Close Menu

NEW YORK (GenomeWeb) –Axiogenesis today announced it has sublicensed patents from GE Healthcare to allow the German cell supplier to commercialize technologies based on human induced pluripotent stem cells (iPSCs).

Under the terms of the agreement, GE Healthcare will sublicense patents for the use of human iPSCs which will enable Axiogenesis to develop cellular assays and stem cell-derived models of disease for use in drug discovery and toxicity screening.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.